

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
 Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

**NAME: Missak Haigentz, MD**

eRA COMMONS USER NAME (credential, e.g., agency login): MHAIGENTZ

POSITION TITLE: Professor of Medicine, Rutgers RWJMS; Chief, Thoracic and Head & Neck Medical Oncology, Rutgers Cancer Institute of New Jersey

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
University of California at Los Angeles, Los Angeles, CA	B.S.	6/1991	Biology; Concentration in Molecular, Cell, and Developmental Biology
UMDNJ, New Jersey Medical School Newark, NJ	M.D.	5/1995	Medicine
UMDNJ, New Jersey Medical School Newark, NJ	PGY I-III	6/1998	Internal Medicine (Chief Resident, 1997-1998)
New York University School of Medicine New York, NY	PGY IV-VI	6/2001	Hematology/Oncology

**A. Personal Statement**

My career has focused on expertise in the development and conduct of cancer clinical trials, with research leadership bridging academic medicine to community oncology and passion of bringing cancer advances to patients. My notable contributions in National Cancer Trials operations have included service roles on the NCI Operational Efficiency Working Group (OEWG), leadership of Audit teams for ECOG-ACRIN, Directorship of the CPDMU of the NCI-designated Albert Einstein Cancer Center, including service on the Steering Committee of the Einstein/Montefiore Minority/Underserved NCORP (NCI Community Oncology Research Program), and most recently as the founding PI of the Atlantic Health Cancer Consortium, the first Community Site NCORP based in New Jersey. My research interests in thoracic and head and neck cancers and in underserved patient populations has led to leadership of an active NCI sponsored trials portfolio for patients living with HIV/AIDS and past service as Chair of the Non-AIDS Defining Cancers Working Group of the UM1-funded AIDS Malignancy Consortium. Since September 2021, I have joined the faculty of RWJMS and Rutgers CINJ where I have assumed leadership roles as Chief of Thoracic and Head & Neck Medical Oncology and as Clinical Director of Oncology Integration for RWJBarnabas Health. I am excited about my return to academic medicine and in leveraging the tremendous collaborative resources at our NCI-CCC, Rutgers University and across RWJBarnabas Health to advance lung and head & neck cancer research and care throughout the state of New Jersey.

## **B. Positions, Scientific Appointments, and Honors**

### **Employment/Academic Appointments**

7/97-6/98	Chief Resident, Department of Medicine, UMDNJ-New Jersey Medical School
7/01-6/03	Instructor of Medicine, Albert Einstein College of Medicine, Bronx, NY
7/03-6/10	Assistant Professor of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY
7/10-5/15	Associate Professor of Clinical Medicine (Oncology) and Clinical Otorhinolaryngology - Head & Neck Surgery, Albert Einstein College of Medicine, Bronx, NY
2012-3/17	Associate Director, Head & Neck Cancer Service, Montefiore-Einstein Center for Cancer Care, Bronx, NY
7/14-3/17	Associate Director for Clinical Research, Hematology-Oncology Fellowship Training Program, Montefiore-Einstein Cancer Center, Bronx, NY
10/14-3/17	Director, Centralized Protocol and Data Management Unit (Clinical Trials Office), Albert Einstein Cancer Center, Bronx, NY
7/15-3/17	Professor of Clinical Medicine and Clinical Otorhinolaryngology – Head & Neck Cancer, Albert Einstein College of Medicine, Bronx, NY
3/17-6/21	Medical Director, Hematology & Oncology, Atlantic Health System Oncology Service Line
3/17-Present	Adjunct Clinical Professor of Medicine and Clinical Otorhinolaryngology – Head & Neck Cancer, Albert Einstein College of Medicine, Bronx, NY
4/17-6/21	Section Chief, Division of Hematology/Oncology, Morristown Medical Center, Morristown, New Jersey
7/17-6/21	Chairman, Cancer Committee, Morristown Medical Center, Morristown, New Jersey
1/19-9/21	Adjunct Professor, Division of Molecular Medicine, Translational Genomics Research Institute (TGen)
9/21-Present	Professor of Medicine, Rutgers Robert Wood Johnson University Medical School, New Brunswick, New Jersey
9/21-Present	Chief, Thoracic and Head & Neck Medical Oncology, Rutgers Cancer Institute of New Jersey
9/21-Present	Clinical Director of Oncology Integration, RWJBarnabas Health

### **Board Certifications**

1998	Diplomate, American Board of Internal Medicine
2008	ABIM Recertification (Medicine)
2002	Diplomate, Medical Oncology
2012	ABIM Recertification (Medical Oncology)
2022	Enrolled in ABIM Medical Oncology Longitudinal Knowledge Assessment (LKA) Program

### **NCI/Academic Committee Membership**

2001-2006	Member, Data Safety Monitoring Committee, Albert Einstein Cancer Center
2004-2017	Member, Protocol Review Committee, Albert Einstein Cancer Center
2004-2014	Associate Director, CPDMU (Clinical Trials Office), Albert Einstein Cancer Center
2005-Present	Member, ECOG Head and Neck Core Committee
2006-2011	Executive Committee, New York Cancer Consortium (NIH N01-contract)
2008-2010	Operational Efficiency Working Group (OEWG), NCI Clinical Trials Advisory Committee
2010-2015	Editorial Board, Journal of Clinical Oncology
2012-2017	Chair, Non-AIDS Defining Cancer (NADC) Working Group, AIDS Malignancy Consortium (AMC)
2013-2014	Member, Institutional Review Board (West Campus), Albert Einstein College of Medicine
2014-2017	Director, Centralized Protocol & Data Management Unit (CPDMU), Albert Einstein Cancer Center
2014-2017	Steering Committee, Montefiore-Einstein Minority/Underserved NCORP (NIH UG1 funded)
2015-2018	Conquer Cancer Foundation of ASCO Grants Selection Committee
2016	Reviewer, Early Career Reviewer Program, NIH/CSR Clinical Oncology (CONC) Study Section
8/19-5/21	Principal Investigator, Atlantic Health Cancer Consortium NCORP
2021	Member, Clinical Investigations and Precision Therapeutics (CIPT) Program, Rutgers CINJ
2022	Member, Human Research Oversight Committee (HROC), Rutgers CINJ

## **Professional Associations**

1995-Present Member, Alpha Omega Alpha Honor Medical Society  
2000-Present Member, American Society of Clinical Oncology  
2000-Present Member, American Association for Cancer Research  
2003-Present New York Head & Neck Society  
Executive Committee, since 2004; Treasurer, 2010-2013; President-Elect, 2013-2014;  
President, 2014-2015  
2008-Present Member, American Head & Neck Society  
2020-Present Member, International Association for the Study of Lung Cancer

## **Honors and Awards**

1995 Alpha Omega Alpha Honor Medical Society, Elected  
1997-2001 National Research Service Award Recipient (T32)  
2001 ASCO Merit Award Recipient  
2004 ASCO Clinical Research Career Development Award Recipient  
2010-2012 NIH K12 Calabresi Scholar, Albert Einstein College of Medicine  
2014-2015 President, New York Head & Neck Society  
2022 Rutgers CINJ Investigator-Initiated Clinical and Translational Pilot Project Award; Alternating Treatment plans for patients with Advanced Thoracic/HN cancers (ATATcH); CINJ 032201, NCT05358548  
2023 Rutgers CINJ Investigator-Initiated Clinical and Translational Pilot Project Award; Phase II Evaluation of Cetuximab/Paclitaxel in patients with recurrent/metastatic Head and Neck Cancer with disease progression on immune checkpoint inhibitors (CetPath); In Development

## **C. Contributions to Science**

### **1) Contributions to NCI Trials Operations**

- Coauthored recommendations from the Operational Efficiency Working Group (OEWG) of the NCI Clinical Trials Advisory Committee
- Leadership roles on NCI funded Trials Consortia: Executive Committee of the New York Cancer Consortium (N01 contract); Steering Committee of the Montefiore-Einstein Minority/Underserved NCORP
- AIDS Malignancy Consortium: Chair, Non-AIDS Defining Cancers Working Group, 2012-2017
- ECOG-ACRIN: Head and Neck Core Committee; Leadership of Site Audit teams
- Albert Einstein Cancer Center: Director, Centralized Protocol and Data Management Unit (CPDMU, Clinical Trials Office)
- NCI Community Oncology Research Program (NCORP) Principal Investigator, Atlantic Health Cancer Consortium, 8/2019-5/2021 [NIH/NCI 1UG1 CA239772]

### **2) Research in HIV-Associated Cancers**

The HIV/AIDS epidemic, now in its 4<sup>th</sup> decade, has seen major shifts in epidemiology, with survival of infected persons increasingly approximating that of the general population and resulting in an aging population increasingly susceptible to cancer. Furthermore, cancer, a historically important manifestation of HIV/AIDS, has also had changed epidemiology over time, where the prevalence of the “non-AIDS-defining” cancers” (including cancers of the lungs, liver, head & neck, and anus – all seen in excess among HIV-infected populations) now exceeds that of the AIDS-defining cancers (Kaposi sarcoma, non-Hodgkin lymphoma and cervical carcinoma). I have developed particular academic interest in these malignancies in HIV infection and have served as Chair the Non-AIDS Defining Cancers (NADC) Working Group of the NIH UM1-funded AIDS Malignancy Clinical Trials Consortium (AMC) from 2012-2017. Under my leadership, this Working Group has generated a national early phase trials portfolio for patients with NADC, an underserved patient population, including AMC-078 [NCT01249443; PI, manuscript published, *Oncologist* 2022, PMID: 35429391], AMC-087 [NCT01822522, PI, completed accrual, manuscript in preparation] and AMC-095 [NCT02408861]. This experience, as well as service on the AMC Outreach, Education and Retention Committee has strengthened my passion to improve access to cancer care advances to underserved populations.

- McLemore MS, **Haigentz M Jr**, Smith RV, Nuovo GJ, Alos L, Cardesa A, Brandwein-Gensler M: Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. *Head Neck Pathol.* 2010;4:97-105

- Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Grecitano J, Sullivan R, Henry DH, Ratner L, **Haigentz M Jr**, Dowlati A, Little RF, Ivy SP, Deeken JF: A phase I/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium Trial AMC 061. *Cancer.* 2014;120:1194-1202

-Anampa J, Barta SK, **Haigentz M**, Sparano JA: Human Immunodeficiency Virus (HIV) Infection and Cancer (Chapter 62), in Armitage JO (Ed): *Abeloff's Clinical Oncology*, 6<sup>th</sup> Edition, Elsevier, 2019

- **Haigentz M Jr**, Moore P, Bimali M, Cooley T, Sparano J, Rudek M, Ratner L, Henry D, Ramos J, Deeken, J, Rubinstein P, Chiao E. Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. *Oncologist* 2022; 27(8):623-e624, 2022. doi: 10.1093/oncolo/oyac004.

### 3) Accrual to NIH-funded Clinical Trials for Patients with Head & Neck Cancer

#### **N01-funded trials**

- **Haigentz M Jr**, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI: Phase II trial of the histone deacetylase (HDAC) inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. *Oral Oncol.* 2012;48:1281-1288 [translational studies supported by NIH/NCI R21 CA110342; PI: Haigentz]

- Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Hayes DN, **Haigentz M Jr**, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH: A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. *Oral Oncol.* 2015;51:376-382

#### **ECOG-ACRIN trials**

- Gilbert J, Collins A, Lee J, Argiris A, **Haigentz M Jr**, Feld L, Jang M, Arun P, Van Waes C, Forastiere A: Phase II two arm trial of the proteasome inhibitor, PS-341 (VELCADE™) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. *Head Neck.* 2013;35:942-948

-Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, **Haigentz M Jr**, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B: Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. *J Clin Oncol.* 2019;37:3266-3274

### 4) Educational Reviews in Head & Neck Cancer

As a clinician-educator, I have had a dedicated role in guiding the academic careers of trainees and in contributing educational reviews on emerging and clinically relevant topics in the field. Examples of recent contributions are below:

- Ow TJ and **Haigentz M Jr**: Tumor Immunology (Chapter 15), In Rosenstreich DL, de Vos GS, and Jackman AH (Eds): *Manual of Allergy and Clinical Immunology for Otolaryngologists*. Plural Publishing, 2015

- Fulcher CD, **Haigentz M Jr**, Ow TJ; Education Committee of the American Head and Neck Society (AHNS). AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. Head Neck. 40: 676-686, 2018

- Attarian S, Ross RB, Koyfman SA, **Haigentz M Jr**: Evaluation and treatment of metastatic lymphadenopathy from an unknown primary (Chapter 20) in Argiris A, Ferris RL and Rosenthal DI (Eds): Head and Neck Cancers: Evidence-based Treatment. Demos Medical Publishing, 2018

**Complete List of Published Work in MyBibliography:**

<https://www.ncbi.nlm.nih.gov/myncbi/missak.haigentz.1/bibliography/public/>